Copeland Capital Management’s iRadimed IRMD Stock Holding History

Copeland Capital Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4M	Buy	391,860 +32,535	+9%	+$2.96M	0.77%	48
2026 Q1	$34.6M	Sell	359,325 -53,225	-13%	-$5.32M	0.77%	50
2025 Q4	$40.1M	Sell	412,550 -20,950	-5%	-$1.8M	0.9%	45
2025 Q3	$30.8M	Sell	433,500 -24,419	-5%	-$1.63M	0.64%	63
2025 Q2	$27.4M	Sell	457,919 -32,625	-7%	-$1.79M	0.56%	75
2025 Q1	$25.7M	Buy	490,544 +14,981	+3%	+$842K	0.52%	78
2024 Q4	$26.2M	Buy	475,563 +53,138	+13%	+$2.8M	0.49%	82
2024 Q3	$21.2M	Buy	422,425 +1,433	+0.3%	+$66.1K	0.37%	93
2024 Q2	$18.5M	Buy	420,992 +2,843	+0.7%	+$121K	0.35%	99
2024 Q1	$18.4M	Buy	418,149 +417,302	+49,268%	+$18.4M	0.33%	93
2023 Q4	$40.2K	Buy	847 +182	+27%	+$7.65K	﹤0.01%	149
2023 Q3	$29.5K	Buy	+665	New	+$30.9K	﹤0.01%	174

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Copeland Capital Management's IRMD Position: Q2 2026 in Review

Copeland Capital Management increased its iRadimed (IRMD) stake by 9.1% in Q2 2026, buying an estimated $2.96M and bringing the position to 391,860 shares worth $37.4M. The position accounts for 0.77% of the portfolio, ranked #48.

Copeland Capital Management first reported a position in IRMD in Q3 2023 and has held it in 12 quarters since. The position peaked at $40.1M in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Copeland Capital Management held 391,860 shares of iRadimed worth $37.4M as of Q2 2026.
Copeland Capital Management bought 32,535 iRadimed shares in Q2 2026, an estimated $2.96M.
iRadimed made up 0.77% of Copeland Capital Management's portfolio in Q2 2026, its #48 holding.
Copeland Capital Management first reported a position in iRadimed in Q3 2023 and has held it in 12 quarters since.
Copeland Capital Management's iRadimed position peaked at $40.1M in Q4 2025.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.